en English

Response from the GPhC to our letter dated 10.02.21

We wrote to The General Pharmaceutical Council (GPhC) expressing our concern that recent regulatory action might discriminate against the trans community. They responded, clarifying their support for transgender patients and outlining their commitment to safeguarding.

 

Read the full letter

 

Photo by STIL on Unsplash